Skip to main content
SpringerLink
Log in

Können SGLT-2-Inhibitoren das Risiko einer diabetischen Retinopathie vermindern?

Can SGLT-2 inhibitors decrease the risk of diabetic retinopathy?

  • Journal Club
  • Published:
Die Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Inzucchi SE, Wanner C, Hehnke U et al (2019) Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care 42(4):e53–e55

    Article  PubMed  Google Scholar 

  2. Li C, Zhou Z, Neuen BL et al (2021) Sodium-glucose co-transporter‑2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 23(1):252–257

    Article  CAS  PubMed  Google Scholar 

  3. Ma Y, Lin C, Cai X et al (2022) The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 15(7):877–886

    Article  PubMed  Google Scholar 

  4. Zhou B, Shi Y, Fu R et al (2022) Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol 13:907340

    Article  Google Scholar 

  5. DeFronzo RA, Reeves WB, Awad AS (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 17(5):319–334

    Article  CAS  PubMed  Google Scholar 

  6. Wong CW, Wong TY, Cheng CY, Sabanayagam C (2014) Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int 85(6):1290–1302

    Article  PubMed  Google Scholar 

  7. Lahoti S, Nashawi M, Sheikh O, Massop D, Mir M, Chilton R (2020) Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab 10(1):3–13

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hu Y, Xu Li QH et al (2022) Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1/2/CPLA2/AA/ROS pathway independent of hypoglycemic. Front Pharmacol 13:827896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wakisaka M, Nagao T (2017) Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology 27(8):691–695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wakisaka M, Yoshinari M, Asano T et al (1999) Normalization of glucose entry under the high glucose condition by phlorizin attenuates the high glucose-induced morphological and functional changes of cultured bovine retinal pericytes. Biochim Biophys Acta 1453(1):83–91

    Article  CAS  PubMed  Google Scholar 

  11. Hanaguri J, Yokota H, Kushiyama A et al (2022) The effect of sodium-dependent glucose cotransporter 2 inhibitor tofogliflozin on neurovascular coupling in the retina in type 2 diabetic mice. Int J Mol Sci 23(3):1362

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Matthews J, Herat L, Rooney J, Rakoczy E, Schlaich M, Matthews VB (2022) Determining the role of SGLT2 inhibition with empagliflozin in the development of diabetic retinopathy. Biosci Rep 42(3):BSR20212209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetesschwerpunktpraxis, Rodensteinstr. 32, 13593, Berlin, Deutschland

    Michael Jecht

Authors
  1. Michael Jecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Jecht.

Ethics declarations

Interessenkonflikt

M. Jecht gibt an, dass kein Interessenkonflikt besteht.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jecht, M. Können SGLT-2-Inhibitoren das Risiko einer diabetischen Retinopathie vermindern?. Diabetologie (2024). https://doi.org/10.1007/s11428-024-01178-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11428-024-01178-w

Search

Navigation